Skip to Content

Incruse Ellipta Approval History

FDA Approved: Yes (First approved April 30, 2014)
Brand name: Incruse Ellipta
Generic name: umeclidinium
Dosage form: Inhalation Powder
Company: GlaxoSmithKline
Treatment for: COPD, Maintenance

Incruse Ellipta (umeclidinium) is an anticholinergic bronchodilator indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

Development History and FDA Approval Process for Incruse Ellipta

DateArticle
May  1, 2014Approval FDA Approves Incruse Ellipta (umeclidinium) for the Treatment of COPD

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide